| Autor: |
Yalcin Mutlu, Melek, Taubmann, Jule, Wacker, Jochen, Tascilar, Koray, Fagni, Filippo, Gerner, Maximilian, Klett, Daniel, Schett, Georg, Manger, Bernhard, Simon, David |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Medicine. 9 |
| ISSN: |
2296-858X |
| DOI: |
10.3389/fmed.2022.934169 |
| Popis: |
Patients with immune-mediated diseases (IMID) such as systemic sclerosis (SSc), who are treated with B cell depleting treatments, are at risk for developing severe COVID-19 due to inadequate humoral immune response. During B cell depletion, therapeutic substitution of neutralizing monoclonal antibodies against the SARS-CoV-2 spike protein (mAbs) might be helpful to prevent severe COVID-19. It has been shown, that in non-IMID patients mABs reduce SARS-CoV-2 viral load and lower the risk of COVID-19 associated hospitalization or death. However, there are limited data on the effect of mAbs in IMID patients after exposure, especially in patients treated with B cell depleting agents. Herein, we report a case of a rituximab treated SSc patient who developed COVID-19 and was successfully treated with a combination of mAbs (casirivimab/imdevimab). With this case we show that IMID patients may benefit from post-exposure administration of mAbs. In our case treatment with neutralizing autoantibodies was safe and a possible contributor in protecting the patient from mechanical ventilation and eventually death. We frame this case within the current evidence from the literature and provide a perspective on the future potential role of mAbs for treating IMID patients suffering from COVID-19. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
